Eighth Edition - R.3 - Human Fertilisation & Embryology Authority

Index
identity verification before donation 11.6
implications of donation 11.13d
importance of informing children about T63(6), 20A,
20.7–20.8
to inform centre of inherited condition 11.23
information T58(4), 4A, 11.24–11.25
about children born 11B, 11.26–11.28, 20B,
20.10, 30B, 30.13
before consent
T58(4), 4A
for egg providers see egg donors/providers
on freezing facilities and storage implications 4.2i
on health/welfare 22.7d, 22.10d
on importing gametes/embryos 16.1
for men donating embryos 5.20b, 11.25b
on research/training 4A, 22B, 22.6–22.11
on screening requirement 4.2h
on storage 17.12
information about, for
donor-conceived people 11.29–11.31, 30B, 30.14–30.16
access to 20B, 20.10–20.14
date for identifying information access 11.30, 20.12
disclosure see above
on egg providers 12.24c
identifying information 11.30, 20.12, 30.13
non-identifying information 11.29, 20.1, 20.11,
30.14, 30.16
warning before disclosure 11.31, 30.13
information collected/held by centre 11.24h
legal parenthood and see legal parenthood
medical/laboratory tests 11.15–11.16
men donating embryos 5.20, 11.25
non-discriminatory/fair recruitment procedures 11.14
non-identifying information about 11.29, 30.14, 30.16
disclosure 11.24i, 11.24j, 20.1,
20.11, 30.14, 30.16
notification of heritable
condition/carrier status 11.21, 11.22d
to patient 11.22b, 11.22c
number of families using 5.18
payments for see payments for donors
primary centre for 11.7a
ensuring 10 family limit 11.36, 11.38
notification of heritable condition 11.22a
notification of secondary centres,
six-family alert 11.38
notification of use of gametes 11.7b, 11.37, 11.39
reassurance over information disclosures 30.16
recording/log of payments 13.10
records, contents required
T46(31)
recruiting centre for, informing of
medical conditions 11.24d
refusal by centre 11.17–11.20
for research/training purposes
counselling
3A
information provision before 4A, 22B, 22.6–22.11
treatment not affected by 22.7f, 22.10f
E
see also research; training
screening T52(11), 11.15, 11.24a, 11.24b
for chlamydia
T52e(11)
for CMV
T52f(11)
egg donors/providers 12.6c, 12.26e
for HIV/HBV/HCV
T52b(11)
for HTLV1
T52g(11)
information for people treated 20.3
qualified laboratory to carry out T51(17), T53a(11)
in surrogacy arrangement
14A
for syphilis
T52b(11), T52d(11)
secondary centre for
10 family limit control 11.36, 11.37, 11.39
notification by primary centre
on treatment 11.38
notification of primary centre
on treatment 11.7b, 11.37, 11.39
selection
basis for and personal interview
T52a(11)
negative for Chlamydia
T52e(11)
negative for HIV1/2, HCV, HBV, syphilis T52b(11)
prohibitions
T55(11)
sued for damages over disability 11.24m
suitability 11A, 11.11–11.14
documenting reason for use 11.12
implications to child 11.13e
reviewing 11.20
risk factors affecting 11A, 11.9a, 11.17
use of donor with abnormality T55(11), 11.11
unsuitability as 11.17–11.20
recording reasons 11.18
unsuspected heritable conditions 11.21–11.23
use in non-medical facility services
3A
voluntary and unpaid T69(13), 13.8
welfare of child risk assessment not needed for 8.5
as witness 18.13
see also egg donors/providers;
sperm donors/donations
egg(s)
in vitro matured, information about
4.2(l)
mixing of cryopreserved
with fresh eggs not allowed
T84b(17)
mixing with sperm, witnessing 18.4d
reduced number, in ICSI 21.1a
use, egg provider’s consent 5.21, 12.7
egg collection
patient/donor identification 18.18
third party agreements 24.1a
witnessing 18.4a, 18.12
egg donors/providers
age of 11.3, 11.4
agreement with centre 12.14–12.21, 12.30
Human Fertilisation and Embryology Authority
Index
Version 3.0